Citigroup’s Axsome Therapeutics AXSM Stock Holding History

Citigroup’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-12,000	Closed	-$1.02M	–	5577
2024 Q4	$1.02M	Sell	12,000 -13,000	-52%	-$1.2M	﹤0.01%	3353
2024 Q3	$2.25M	Buy	+25,000	New	+$2.18M	﹤0.01%	2570
2023 Q4	–	Sell	-27,400	Closed	-$1.91M	–	5696
2023 Q3	$1.91M	Buy	+27,400	New	+$2.05M	﹤0.01%	2011
2022 Q3	–	Sell	-25,300	Closed	-$969K	–	5823
2022 Q2	$969K	Buy	+25,300	New	+$800K	﹤0.01%	2681
2021 Q1	–	Sell	-15,200	Closed	-$1.24M	–	6256
2020 Q4	$1.24M	Buy	15,200 +9,800	+181%	+$733K	﹤0.01%	3328
2020 Q3	$385K	Buy	5,400 +2,900	+116%	+$226K	﹤0.01%	4077
2020 Q2	$206K	Buy	+2,500	New	+$192K	﹤0.01%	4992

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citigroup's AXSM Position: Q2 2026 in Review

Citigroup reduced its Axsome Therapeutics (AXSM) stake by 26% in Q2 2026, selling an estimated $10.6M and leaving 136,858 shares worth $33.5M. The position accounts for 0.01% of the portfolio, ranked #908.

Citigroup first reported a position in AXSM in Q2 2016 and has held it in 35 quarters since. The position peaked at $37.3M in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Citigroup held 136,858 shares of Axsome Therapeutics worth $33.5M as of Q2 2026.
Citigroup sold 48,800 Axsome Therapeutics shares in Q2 2026, an estimated $10.6M.
Axsome Therapeutics made up 0.01% of Citigroup's portfolio in Q2 2026, its #908 holding.
Citigroup first reported a position in Axsome Therapeutics in Q2 2016 and has held it in 35 quarters since.
Citigroup's Axsome Therapeutics position peaked at $37.3M in Q4 2025.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.